PMID- 18156722
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120823
LR  - 20191110
IS  - 1598-6535 (Print)
IS  - 1598-6535 (Linking)
VI  - 26
IP  - 3
DP  - 2006 Jun
TI  - [Clinical Usefulness of Antimicrobial Susceptibility Test for Helicobacter 
      pylori.].
PG  - 179-84
AB  - BACKGROUND: Antimicrobial resistance of Helicobacter pylori is considered as the 
      main cause of failure of eradication therapy. Because resistance to metronidazole 
      has been reported in 25.8% to 66.2% of H. pylori, a combination of proton pump 
      inhibitors (PPI), amoxicillin, and clarithromycin is currently recommended as a 
      primary therapy. We investigated the prevalence of antimicrobial resistance to 
      the primary drugs and the impact of antimicrobial resistance on eradication 
      rates. METHODS: Between May and August 2005, H. pylori isolates from 93 patients 
      were tested for antimicrobial susceptibility at Asan Medical Center. 
      Susceptibility tests of clarithromycin and amoxicillin were performed by the disk 
      diffusion method and those of metronidazole and tetracycline by Etest (AB 
      Biodisk, Solna, Sweden). The medical records of the patients were reviewed to 
      collect the data such as demographic findings, previous and current eradication 
      therapies, and bacteriological outcome. The appropriate therapy was defined as 
      three-drug-combination including susceptible drugs only, or four-drug-combination 
      including metronidazole in the case of metronidazole-resistance. RESULTS: 
      Resistance rates to clarithromycin and metronidazole were 17.2% and 33.3%, 
      respectively, but there was no resistance to tetracycline and amoxicillin. The 
      eradication was successful in 32 of the 36 patients (88.9%) who received the 
      appropriate therapy, but none of 4 patients who received an inappropriate therapy 
      (P<0.01). CONCLUSIONS: Resistance to clarithromycin seemed to increase and 
      contribute to the failure of eradication therapy. For the appropriate therapy of 
      H. pylori infection, the susceptibility results should be reported before 
      initiation of the eradication therapy.
FAU - Sung, Heungsup
AU  - Sung H
AD  - Department of Laboratory Medicine, University of Ulsan College of Medicine and 
      Asan Medical Center, Seoul, Korea. mnkim@amc.seoul.kr.
FAU - Chung, Hee Jung
AU  - Chung HJ
FAU - Kim, Mi Na
AU  - Kim MN
FAU - Lee, Gin Hyug
AU  - Lee GH
LA  - kor
PT  - English Abstract
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Lab Med
JT  - The Korean journal of laboratory medicine
JID - 101322822
EDAT- 2007/12/25 09:00
MHDA- 2007/12/25 09:01
CRDT- 2007/12/25 09:00
PHST- 2007/12/25 09:00 [pubmed]
PHST- 2007/12/25 09:01 [medline]
PHST- 2007/12/25 09:00 [entrez]
AID - 200606179 [pii]
AID - 10.3343/kjlm.2006.26.3.179 [doi]
PST - ppublish
SO  - Korean J Lab Med. 2006 Jun;26(3):179-84. doi: 10.3343/kjlm.2006.26.3.179.